Contemporary practice patterns of tyrosine kinase inhibitor use among older patients with chronic myeloid leukemia in the United States

Introduction: The choice of BCR-ABL1 tyrosine kinase inhibitors (TKI) for the first line of therapy (LOT) for chronic-phase chronic myeloid leukemia (CML) is tailored to disease risk and patient characteristics like comorbidities, which become more prevalent with age. However, contemporary evaluatio...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Rory M. Shallis, Rong Wang, Jan P. Bewersdorf, Amer M. Zeidan, Amy J. Davidoff, Scott F. Huntington, Nikolai A. Podoltsev, Xiaomei Ma
Formato:	article
Lenguaje:	EN
Publicado:	SAGE Publishing 2021
Materias:	Diseases of the blood and blood-forming organs RC633-647.5
Acceso en línea:	https://doaj.org/article/f9cb5ac8d0f14aa8b6c4e76d443c97fb
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:f9cb5ac8d0f14aa8b6c4e76d443c97fb
record_format	dspace
spelling	oai:doaj.org-article:f9cb5ac8d0f14aa8b6c4e76d443c97fb2021-12-01T00:05:36ZContemporary practice patterns of tyrosine kinase inhibitor use among older patients with chronic myeloid leukemia in the United States2040-621510.1177/20406207211043404https://doaj.org/article/f9cb5ac8d0f14aa8b6c4e76d443c97fb2021-11-01T00:00:00Zhttps://doi.org/10.1177/20406207211043404https://doaj.org/toc/2040-6215Introduction: The choice of BCR-ABL1 tyrosine kinase inhibitors (TKI) for the first line of therapy (LOT) for chronic-phase chronic myeloid leukemia (CML) is tailored to disease risk and patient characteristics like comorbidities, which become more prevalent with age. However, contemporary evaluations of frontline TKI choice and the factors associated with TKI switching in this specific patient population are lacking. Methods: We sought to describe TKI use in older patients (age: 66–99 years) with CML in the United States. Using the Surveillance, Epidemiology, and End Results–Medicare-linked database, we identified 810 older (median age: 75 years, interquartile range: 70–80 years) patients diagnosed during 2007–2015. Results: Imatinib was the most common frontline TKI (63.1%) throughout the study period, but its utilization as such decreased from 76% in 2010 to 47% in 2015. Most patients (65.3%) used only one TKI, but 12.5% of the 281 patients who switched from frontline TKI received ⩾4 LOT. Among the 167 patients switching from frontline imatinib, 18.6% eventually returned to imatinib with nearly all as the third LOT, supporting its favorable safety profile and indicating that the initial switch from imatinib might have been premature. Older patients within our cohort, white patients and those with greater comorbidity were less likely to switch from frontline TKI. Diagnosis year, geographic region, and surrogates for socioeconomic status and healthcare access had no impact on TKI switching. Conclusion: As expected, our findings highlight the frequent use of imatinib as the treatment option for older CML patients despite the availability of second-generation TKIs.Rory M. ShallisRong WangJan P. BewersdorfAmer M. ZeidanAmy J. DavidoffScott F. HuntingtonNikolai A. PodoltsevXiaomei MaSAGE PublishingarticleDiseases of the blood and blood-forming organsRC633-647.5ENTherapeutic Advances in Hematology, Vol 12 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Diseases of the blood and blood-forming organs RC633-647.5
spellingShingle	Diseases of the blood and blood-forming organs RC633-647.5 Rory M. Shallis Rong Wang Jan P. Bewersdorf Amer M. Zeidan Amy J. Davidoff Scott F. Huntington Nikolai A. Podoltsev Xiaomei Ma Contemporary practice patterns of tyrosine kinase inhibitor use among older patients with chronic myeloid leukemia in the United States
description	Introduction: The choice of BCR-ABL1 tyrosine kinase inhibitors (TKI) for the first line of therapy (LOT) for chronic-phase chronic myeloid leukemia (CML) is tailored to disease risk and patient characteristics like comorbidities, which become more prevalent with age. However, contemporary evaluations of frontline TKI choice and the factors associated with TKI switching in this specific patient population are lacking. Methods: We sought to describe TKI use in older patients (age: 66–99 years) with CML in the United States. Using the Surveillance, Epidemiology, and End Results–Medicare-linked database, we identified 810 older (median age: 75 years, interquartile range: 70–80 years) patients diagnosed during 2007–2015. Results: Imatinib was the most common frontline TKI (63.1%) throughout the study period, but its utilization as such decreased from 76% in 2010 to 47% in 2015. Most patients (65.3%) used only one TKI, but 12.5% of the 281 patients who switched from frontline TKI received ⩾4 LOT. Among the 167 patients switching from frontline imatinib, 18.6% eventually returned to imatinib with nearly all as the third LOT, supporting its favorable safety profile and indicating that the initial switch from imatinib might have been premature. Older patients within our cohort, white patients and those with greater comorbidity were less likely to switch from frontline TKI. Diagnosis year, geographic region, and surrogates for socioeconomic status and healthcare access had no impact on TKI switching. Conclusion: As expected, our findings highlight the frequent use of imatinib as the treatment option for older CML patients despite the availability of second-generation TKIs.
format	article
author	Rory M. Shallis Rong Wang Jan P. Bewersdorf Amer M. Zeidan Amy J. Davidoff Scott F. Huntington Nikolai A. Podoltsev Xiaomei Ma
author_facet	Rory M. Shallis Rong Wang Jan P. Bewersdorf Amer M. Zeidan Amy J. Davidoff Scott F. Huntington Nikolai A. Podoltsev Xiaomei Ma
author_sort	Rory M. Shallis
title	Contemporary practice patterns of tyrosine kinase inhibitor use among older patients with chronic myeloid leukemia in the United States
title_short	Contemporary practice patterns of tyrosine kinase inhibitor use among older patients with chronic myeloid leukemia in the United States
title_full	Contemporary practice patterns of tyrosine kinase inhibitor use among older patients with chronic myeloid leukemia in the United States
title_fullStr	Contemporary practice patterns of tyrosine kinase inhibitor use among older patients with chronic myeloid leukemia in the United States
title_full_unstemmed	Contemporary practice patterns of tyrosine kinase inhibitor use among older patients with chronic myeloid leukemia in the United States
title_sort	contemporary practice patterns of tyrosine kinase inhibitor use among older patients with chronic myeloid leukemia in the united states
publisher	SAGE Publishing
publishDate	2021
url	https://doaj.org/article/f9cb5ac8d0f14aa8b6c4e76d443c97fb
work_keys_str_mv	AT rorymshallis contemporarypracticepatternsoftyrosinekinaseinhibitoruseamongolderpatientswithchronicmyeloidleukemiaintheunitedstates AT rongwang contemporarypracticepatternsoftyrosinekinaseinhibitoruseamongolderpatientswithchronicmyeloidleukemiaintheunitedstates AT janpbewersdorf contemporarypracticepatternsoftyrosinekinaseinhibitoruseamongolderpatientswithchronicmyeloidleukemiaintheunitedstates AT amermzeidan contemporarypracticepatternsoftyrosinekinaseinhibitoruseamongolderpatientswithchronicmyeloidleukemiaintheunitedstates AT amyjdavidoff contemporarypracticepatternsoftyrosinekinaseinhibitoruseamongolderpatientswithchronicmyeloidleukemiaintheunitedstates AT scottfhuntington contemporarypracticepatternsoftyrosinekinaseinhibitoruseamongolderpatientswithchronicmyeloidleukemiaintheunitedstates AT nikolaiapodoltsev contemporarypracticepatternsoftyrosinekinaseinhibitoruseamongolderpatientswithchronicmyeloidleukemiaintheunitedstates AT xiaomeima contemporarypracticepatternsoftyrosinekinaseinhibitoruseamongolderpatientswithchronicmyeloidleukemiaintheunitedstates
_version_	1718406178910765056

Contemporary practice patterns of tyrosine kinase inhibitor use among older patients with chronic myeloid leukemia in the United States

Ejemplares similares